WO1998041232A3 - Compositions for modulating responsiveness to corticosteroids - Google Patents

Compositions for modulating responsiveness to corticosteroids Download PDF

Info

Publication number
WO1998041232A3
WO1998041232A3 PCT/US1998/004916 US9804916W WO9841232A3 WO 1998041232 A3 WO1998041232 A3 WO 1998041232A3 US 9804916 W US9804916 W US 9804916W WO 9841232 A3 WO9841232 A3 WO 9841232A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
corticosteroid
subject
preferred
antagonist
Prior art date
Application number
PCT/US1998/004916
Other languages
French (fr)
Other versions
WO1998041232A2 (en
Inventor
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Original Assignee
Basf Ag
Les Sekut
Adam Carter
Tariq Ghayur
Subhashis Banerjee
Daniel E Tracey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Priority to CA002282845A priority Critical patent/CA2282845A1/en
Priority to IL13181598A priority patent/IL131815A0/en
Priority to HU0104439A priority patent/HUP0104439A3/en
Priority to SK1221-99A priority patent/SK122199A3/en
Priority to JP54063398A priority patent/JP2002504091A/en
Priority to EP98912929A priority patent/EP0998300A1/en
Priority to BR9810409-8A priority patent/BR9810409A/en
Application filed by Basf Ag, Les Sekut, Adam Carter, Tariq Ghayur, Subhashis Banerjee, Daniel E Tracey filed Critical Basf Ag
Priority to SI9820032A priority patent/SI20110A/en
Priority to AU67604/98A priority patent/AU734756B2/en
Priority to NZ337769A priority patent/NZ337769A/en
Priority to DE0998300T priority patent/DE998300T1/en
Publication of WO1998041232A2 publication Critical patent/WO1998041232A2/en
Priority to NO994506A priority patent/NO994506L/en
Priority to BG103808A priority patent/BG103808A/en
Publication of WO1998041232A3 publication Critical patent/WO1998041232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Method for modulating responsiveness to corticosteroids in a subjet are provided. In the method of the invention, an agent which antagonizes a target that regulates production of IFN-η in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a target that regulates production of IFN-η in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.
PCT/US1998/004916 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids WO1998041232A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE0998300T DE998300T1 (en) 1997-03-18 1998-03-12 COMPOSITIONS FOR MODULATING SENSITIVITY TO CORTICOSTEROIDS
BR9810409-8A BR9810409A (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
HU0104439A HUP0104439A3 (en) 1997-03-18 1998-03-12 Pharmaceutical compositions for modulating responsiveness to corticosteroids and use thereof
SK1221-99A SK122199A3 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
SI9820032A SI20110A (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
EP98912929A EP0998300A1 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
IL13181598A IL131815A0 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
CA002282845A CA2282845A1 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
JP54063398A JP2002504091A (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
AU67604/98A AU734756B2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids
NZ337769A NZ337769A (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids
NO994506A NO994506L (en) 1997-03-18 1999-09-17 Methods and compositions for modulating susceptibility to corticosteroids
BG103808A BG103808A (en) 1997-03-18 1999-10-13 Methods and compositions for modulation responsiveness to corticosteroids

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US08/820,692 1997-03-18
US1634698A 1998-01-30 1998-01-30
US09/016,346 1998-10-30

Publications (2)

Publication Number Publication Date
WO1998041232A2 WO1998041232A2 (en) 1998-09-24
WO1998041232A3 true WO1998041232A3 (en) 2000-10-05

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (en)
JP (1) JP2002504091A (en)
KR (1) KR20000076420A (en)
CN (1) CN1269722A (en)
AU (1) AU734756B2 (en)
BG (1) BG103808A (en)
BR (1) BR9810409A (en)
CA (1) CA2282845A1 (en)
DE (1) DE998300T1 (en)
ES (1) ES2146192T1 (en)
HU (1) HUP0104439A3 (en)
ID (1) ID22975A (en)
IL (1) IL131815A0 (en)
NO (1) NO994506L (en)
NZ (1) NZ337769A (en)
PL (1) PL336464A1 (en)
SI (1) SI20110A (en)
SK (1) SK122199A3 (en)
TR (1) TR199902615T2 (en)
WO (1) WO1998041232A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945545B2 (en) 2008-03-18 2015-02-03 Abbvie Inc. Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US9198885B2 (en) 2005-07-14 2015-12-01 Neothetics, Inc. Lipolytic methods for regional adiposity comprising salmeterol or formoterol
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (en) * 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
EP0969867B1 (en) * 1997-10-31 2004-09-01 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CN1297354A (en) * 1998-03-16 2001-05-30 西托维亚公司 Dipeptide caspase inhibitors and use thereof
EP1140206A4 (en) * 1998-11-27 2002-04-10 Technion Res & Dev Foundation Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
JP3579355B2 (en) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド Psoriasis model animals for preventing and treating human psoriasis
ATE336480T1 (en) 1999-03-16 2006-09-15 Cytovia Inc SUBSTITUTED 2-AMINOBENZAMIN CASPASE INHIBITORS AND THEIR USE
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
DE19915465A1 (en) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes
BR0009610A (en) 1999-04-09 2002-02-13 Cytovia Inc Caspase inhibitors and their use
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CA2383002A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
ES2267778T3 (en) * 2000-06-06 2007-03-16 Glaxo Group Limited COMPOSITION FOR THE TREATMENT OF CANCER, CONTAINING AN ANTI-NEOPLASTIC AGENT AND A PDE4 INHIBITOR.
AU7250301A (en) * 2000-06-22 2002-01-02 Willy Ben Moussa Ben Mohammed Use of glucocorticosteroids for producing a medicament to treat oligotrichia
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EA010180B1 (en) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Use of il-18 inhibitors in the preparation of a medicament for the treatment and/or prevention of cardiomyopathy
ES2334773T3 (en) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. USE OF IL-18 INHIBITORS FOR THE TREATMENT OR PREVENTION OF SEPSIS.
TR201809008T4 (en) 2001-06-26 2018-07-23 Amgen Fremont Inc Antibodies against opgl.
US7253155B2 (en) * 2001-10-05 2007-08-07 Combinatorx, Inc. Combinations for the treatment of immunoinflammatory disorders
JP2003342196A (en) * 2002-05-31 2003-12-03 Mukku:Kk Composition for intravenous injection, method of production for the same and its preparation
BR0314713A (en) * 2002-09-24 2005-07-26 Combinatorx Inc Processes and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines.
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005110450A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP5595632B2 (en) 2004-07-16 2014-09-24 敦生 関山 IL-18 receptor antagonist and pharmaceutical composition comprising said antagonist
WO2006041121A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
JP2010506941A (en) * 2006-10-17 2010-03-04 リセラ，インク． Methods, compositions and formulations for the treatment of thyroid ophthalmopathy
CN104524567A (en) 2007-01-16 2015-04-22 阿布维公司 Methods for treating psoriasis
KR20100014674A (en) 2007-03-29 2010-02-10 아보트 러보러터리즈 Crystalline anti-human il-12 antibodies
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
EP4291162A1 (en) 2021-02-10 2023-12-20 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
CA3231766A1 (en) * 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
EP0416950A1 (en) * 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments
WO1993011743A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
WO1993015741A1 (en) * 1992-02-06 1993-08-19 Glaxo Group Limited Medicaments
WO1994003153A1 (en) * 1992-07-31 1994-02-17 Glaxo Group Limited Surfactant free aerosol formulations containing beclomethasone dipropionate
WO1996019968A1 (en) * 1994-12-24 1996-07-04 Glaxo Group Limited Pharmaceutical aerosol containing at least one sugar
WO1996032345A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
EP0416950A1 (en) * 1989-09-08 1991-03-13 Glaxo Group Limited Medicaments
WO1993011743A1 (en) * 1991-12-12 1993-06-24 Glaxo Group Limited Medicaments
WO1993015741A1 (en) * 1992-02-06 1993-08-19 Glaxo Group Limited Medicaments
WO1994003153A1 (en) * 1992-07-31 1994-02-17 Glaxo Group Limited Surfactant free aerosol formulations containing beclomethasone dipropionate
WO1996019968A1 (en) * 1994-12-24 1996-07-04 Glaxo Group Limited Pharmaceutical aerosol containing at least one sugar
WO1996032345A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for beclomethasone dipropionate

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9198885B2 (en) 2005-07-14 2015-12-01 Neothetics, Inc. Lipolytic methods for regional adiposity comprising salmeterol or formoterol
US9370498B2 (en) 2005-07-14 2016-06-21 Neothetics, Inc. Methods of using lipolytic formulations for regional adipose tissue treatment
US8945545B2 (en) 2008-03-18 2015-02-03 Abbvie Inc. Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Also Published As

Publication number Publication date
CN1269722A (en) 2000-10-11
DE998300T1 (en) 2001-03-01
CA2282845A1 (en) 1998-09-24
AU6760498A (en) 1998-10-12
HUP0104439A3 (en) 2002-08-28
NO994506L (en) 1999-11-17
ID22975A (en) 1999-12-23
NO994506D0 (en) 1999-09-17
HUP0104439A2 (en) 2002-04-29
JP2002504091A (en) 2002-02-05
BG103808A (en) 2000-07-31
SK122199A3 (en) 2000-12-11
ES2146192T1 (en) 2000-08-01
KR20000076420A (en) 2000-12-26
TR199902615T2 (en) 2000-03-21
WO1998041232A2 (en) 1998-09-24
BR9810409A (en) 2000-08-22
EP0998300A1 (en) 2000-05-10
SI20110A (en) 2000-06-30
IL131815A0 (en) 2001-03-19
AU734756B2 (en) 2001-06-21
PL336464A1 (en) 2000-06-19
NZ337769A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
WO1998041232A3 (en) Compositions for modulating responsiveness to corticosteroids
WO2001019373A3 (en) Methods and compositions for modulating responsiveness to corticosteroids
Nothnick Treating endometriosis as an autoimmune disease
CA2274825A1 (en) Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
CA2339253A1 (en) Inhibitors of p38
AU8377698A (en) Inhibitors of p38
WO2005070126A3 (en) Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CA2148907A1 (en) Treatment of inflammatory bowel disease with ifn-gamma inhibitors
HK1033308A1 (en) Glucocorticoid-selective anti-inflammatory agents
MY132496A (en) Inhibitors of p38
CA2123593A1 (en) Method of Treating TNF-Dependent Inflammation Using Tumor Necrosis Factor Antagonists
CA2305394A1 (en) Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
TNSN04001A1 (en) ASSOCIATION OF ALDOSTERONE RECEPTOR ANTAGONIST AND HMG-COA-REDUCTASE INHIBITOR.
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
HUP0000678A3 (en) Aminobenzophenones as inhibitors of interleukin and tnf, process for their preparation and pharmaceutical compositions containing the same
BG105691A (en) Tumor necrosis factor antagonists and their use in endometriosis
BG103016A (en) Polypeptides capable of forming antigen-binding structures of specificity to rhesus d antigens, their encoding dna and method for their prparation and application
WO2000006086A3 (en) Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
WO2002068476A3 (en) Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
IE821828L (en) Blood platelet aggregation inhibitors containing anagrelide

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131815

Country of ref document: IL

Ref document number: 98805124.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2282845

Country of ref document: CA

Ref document number: 2282845

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-3127

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 67604/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 122199

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 337769

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008433

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 99-00997

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1019997008524

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 540633

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999/02615

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1998912929

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

EFNL Nl: laying open to public inspection of translations into the netherlands language of claims of a european patent application

Free format text: NAME AND RESIDENCE OF THE APPLICANT: BASF AKTIENGESELLSCHAFT TE UDWIGSHAFEN, BONDSREPUBLIEK (DE)

WWP Wipo information: published in national office

Ref document number: PV1999-3127

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1998912929

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1019997008524

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 67604/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998912929

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997008524

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-3127

Country of ref document: CZ